FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.502,79 +844,48 (+1,44%)
Theratechnologies Inc. (THTX)
| Chiusura precedente | 1,3000 |
| Aperto | 1,3600 |
| Denaro | 0,9432 x 200 |
| Lettera | 1,6800 x 200 |
| Min-Max giorno | 1,3000 - 1,3656 |
| Intervallo di 52 settimane | 0,8800 - 4,3200 |
| Volume | |
| Media Volume | 34.680 |
| Capitalizzazione | 60,593M |
| Beta (5 anni mensile) | 1,78 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,9100 |
| Prossima data utili | 10 lug 2024 - 15 lug 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 8,67 |
GlobeNewswireTheratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon
- Revised the Minimum Liquidity Covenant for All Times Following October 31, 2023 to be Between US$15 Million and US$20 Million - Minimum Quarterly Revenue Covenant Replaced with Minimum Adjusted EBITDA Covenant - Deleted Prohibition Against Having a Going Concern Note in the Opinion of the Company’s Auditors that Accompanies the Company’s Annual Report This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its
- GlobeNewswire
Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
Significant reduction in INSTI-associated VAT accumulation with tesamorelin contrasts with VAT increase in patients taking placebo VAT accumulation observed after 12 months on INSTI-containing regimens, even in the absence of significant weight or body mass index changesResults also show a reduction in hepatic fat fraction in people taking tesamorelin This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its s
- GlobeNewswire
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced results from a study evaluating an intramuscula
